A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
Study sponsor: Verastem, Inc. · VSTM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-08-29Actual
Enrollment · participants90Actual
Source updated2024-01-12Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.